Agree Pete. As much as we all want to see results, this so called delay is a huge positive for the company. With a greater ROI, the product has become more valuable-relative to expense saved. Whatever that may be.
Exactly Pete, and dont forget that the trial is dosed for only 30 days and then reviewed for just another 30. Then the world will know what we have with a drug that was reported to be very successful in preclinicals, preclinicals that were run by Dr Menon, a professional that has years of experience testing drugs.
It is believed that Prurisol alone will command close to $10/share once proven successful.
The European trial for kevetrin is scheduled to start in July, there has been no reason to suspect anything else. Write Leo, and ask, rather then starting rumors that other trials are on hold until..... Different cancers equals different trials.